Welcome to our dedicated page for American Well SEC filings (Ticker: AMWL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Telehealth revenue models, multi-year platform investments, and value-based care contracts make American Well Corporation’s disclosures dense reading. If you have ever searched “American Well SEC filings explained simply” or wondered how board decisions affect the hybrid-care roadmap, you know that a single footnote in the 10-K can change your valuation thesis. Add insider moves and sudden 8-K announcements and the research pile grows quickly.
Our SEC Filings hub removes that friction. The moment EDGAR posts a new document—whether it is an “American Well quarterly earnings report 10-Q filing” or an “American Well 8-K material events explained”—our system flags it, then feeds it to Stock Titan’s AI engine. You receive concise overviews, key metric extractions, and contextual links, so “understanding American Well SEC documents with AI” takes minutes, not late nights. Need to monitor “American Well insider trading Form 4 transactions”? We stream “American Well Form 4 insider transactions real-time” and highlight option grants, automatic sales, and beneficial-owner changes in plain language.
Investors use this page to drill into specifics that drive telehealth economics. The “American Well annual report 10-K simplified” section outlines segment revenue for virtual primary care, platform licensing, and professional services. Each “American Well earnings report filing analysis” tracks visit volumes, payer mix, and margin trends across the care continuum. A dedicated tab surfaces “American Well proxy statement executive compensation” so you can compare stock awards to clinical-outcome targets. Practical use cases include spotting “American Well executive stock transactions Form 4” before earnings calls, mapping deferred revenue shifts across quarters, and following R&D spend tied to strategic partnerships. All filings stay in one place, updated in real time, with AI-powered summaries, expert notes, and full original PDFs ready for deep dives.
Paul McNeice, Chief Accounting Officer of American Well Corp (AMWL), reported a sale of 332 shares of Class A common stock on 10/01/2025 at a price of $6.1064 per share. The filing states the sale was an automatic sell-to-cover to satisfy the tax liability from the vesting and settlement of restricted stock units that occurred the same day. After the transaction, the reporting person beneficially owned 3,560 shares. The Form 4 was signed on behalf of Mr. McNeice by an attorney-in-fact on 10/03/2025.
American Well Corp (AMWL) reported an insider transaction by its President, International, Phyllis Gotlib. On October 1, 2025, she sold 4,959 shares of Class A Common Stock at $6.1064 per share. According to the note, the sale was an automatic “sell-to-cover” to satisfy tax liabilities from the vesting and settlement of restricted stock units, and did not represent a discretionary trade.
After the transaction, her beneficial ownership was 127,151 shares held directly and 114,250 shares held indirectly by her husband.
American Well Corp (AMWL) notice of proposed securities sale under Rule 144. The filing states an intended sale of 4,959 shares of Class A common stock through Morgan Stanley on the NYSE with an aggregate market value of $30,281.64. The filer reports holding 14,162,309 shares outstanding.
The shares were acquired upon vesting of a restricted stock unit grant from American Well Corporation, showing 7,032 RSUs vested on the acquisition date. The filing also discloses two prior sales by the same account in the past three months: 4,958 shares (gross proceeds $42,773.16) and 4,781 shares (gross proceeds $32,422.35).
Deborah C. Jackson, a director of American Well Corp (AMWL), reported a sale of 4,531 shares of Class A common stock on 09/15/2025 at an average price of $6.5647 per share, leaving her with 39,132 shares beneficially owned directly and 612 shares indirectly held by her spouse.
The filing states the sale was executed under a Rule 10b5-1 trading plan adopted May 20, 2025, and the shares were sold to cover tax liabilities from the vesting and settlement of restricted stock units on June 10, 2025. The Form 4 was signed by an attorney-in-fact on behalf of Ms. Jackson on 09/17/2025.
Dmitry Zamansky, Chief Product & Technology Officer of American Well Corporation (AMWL), reported a sale of 25,605 shares of Class A common stock on 09/03/2025 at a price of $6.7724 per share. After the transaction, he beneficially owned 197,711 shares. The Form 4 states the sale was a non-discretionary "sell to cover" to pay tax liabilities arising from the vesting and settlement of restricted stock units on the same date. The filing is signed by an attorney-in-fact on behalf of Mr. Zamansky on 09/04/2025. The disclosure indicates routine insider tax-related selling rather than a voluntary open-market trade by the reporting person.
The filing shows that Deborah C. Jackson, a director of American Well Corporation (AMWL), sold 4,531 shares of Class A common stock on 09/02/2025 at a price of $6.7886 per share. The Form 4 states the sale was executed under a Rule 10b5-1 trading plan adopted on 05/20/2025 to cover tax liabilities arising from the vesting and settlement of restricted stock units on 06/10/2025. After the reported sale, the filing lists 43,663 Class A shares as directly beneficially owned and 612 Class A shares as indirectly owned by spouse. The form is signed by an attorney-in-fact on behalf of the reporting person.
Phyllis Gotlib, President, International of American Well Corp (AMWL), reported a non-discretionary sale of 4,781 shares of Class A common stock on 09/02/2025 at $6.7815 per share to satisfy tax withholding from restricted stock units that vested on 09/01/2025. After the transaction she beneficially owns 132,110 shares directly; an additional 114,250 shares are reported indirectly through her husband. The sale was an automatic "sell-to-cover" and was not a discretionary trade. The Form 4 was signed by an attorney-in-fact on 09/04/2025.
Paul Francis McNeice, Chief Accounting Officer and director of American Well Corporation (AMWL), reported a single transaction on Form 4. On 09/02/2025 he sold 113 shares of Class A common stock at $6.7815 per share, and following the sale he beneficially owns 3,892 shares directly. The filing states the shares were sold to pay the tax liability from restricted stock units that vested and settled on 09/01/2025, executed as an automatic "sell to cover" and not a discretionary trade by the reporting person. The Form 4 was signed by an attorney-in-fact on 09/04/2025.
American Well Corporation (AMWL) filed a Form 144 disclosing a proposed sale of 26,500 Class A common shares through Morgan Stanley on the NYSE with an aggregate market value of $180,661.10. The filing lists total shares outstanding as 14,162,309 and shows the approximate date of sale as 09/03/2025.
The securities were acquired on 09/03/2025 via vesting of a restricted stock unit grant; the filer reports acquisition of 55,211 shares through that grant and indicates no securities sold in the past three months. The filing contains the standard Rule 144 attestation language and a signature block remarking criminal penalties for misstatement.
American Well Corporation (AMWL) Form 144 notifies the market of a proposed sale under Rule 144 of 4,781 Class A common shares with an aggregate market value of $32,422.35, expected to occur on 09/02/2025 on the NYSE. The shares were acquired through the vesting of restricted stock units on 09/01/2025. The filing lists total outstanding Class A shares of 14,162,309 and shows prior sales by the same person on 06/02/2025 (4,782 shares, $31,628.15) and 07/01/2025 (4,958 shares, $42,773.16).
FAQ
What is the current stock price of American Well (AMWL)?
What is the market cap of American Well (AMWL)?
